TPOXX® Antiviral Treatment (Tecovirimat)
Estimated value
£1
Awarded value
£1
Suppliers
1
Lots
1
Published
04 Nov 2022
Description
The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK. Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.
Scope
- Reference
- CF-1166800D0O000000rwimUAA
- Total value
- £1 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 27 Jul 2022 to 26 Jul 2023
- CPV classifications
- 33651400
Submission & procedure
- Submission deadline
- 27 Jul 2022, 11:00 am
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£1
Award date
27 Jul 2022
Contract start
27 Jul 2022
Contract end
26 Jul 2023